http://www.vaclib.org/basic/fluindex.htm
| Vaccination Liberation - Information |
Refusal/Legal: Return to
Index of Articles for Vaccination Liberation.
Avoid Vaccinations: Return
to Index of Articles for Vaccination Liberation.
http://mainelung.org/learn_with_us/lhi2/fluG2.htmlThe following edited information is from the Maine (US) Lung Association website.
There is an excellent graph at
which shows for the years 1979-1998, combined pneumonia and influenza
deaths:
US population 65-74 (graph shows about 60 deaths per 100,000)
US population 75-84 (graph shows about 200-250 deaths per 100,000)
US population 85 and up, (graph shows about 750 up to 1150 (in 1988),
back to over 1000 deaths per 100,000)
"Over the past twenty years, age specific death rates for pneumonia and influenza have increased in the older adult populations (65+ years), and decreased in the childhood population (0-14 years), and have remained relatively constant in other population subgroups.
The national data indicate a significant rise in the age specific pneumonia and influenza death rates among people 85 years and older.
"Source: NCHS, 2000a,b; NCHS 1999. Rates are age adjusted to the 1940 US population.
Nationally, death rates from pneumonia and influenza have remained relatively constant since the 1980s (approximately 12-13 deaths per 100,000 population). ..." [for a population of 280 million X 12/100k = 33,600 deaths. So I think 20,000 is just the flu deaths.]
In the time period that death rates from flu increased in the older sub-population, the following pro vaccine -short course- thoughtfuly informs us that the vaccination rates also increased!
http://www.nursingceu.com/NCEU/courses/influenza/
influenza.html (short course)
Each year, influenza has a mortality cost of over 20,000 lives, particularly
in patients over 65 with chronic co-morbidities. Fortunately, vaccination
levels have risen dramatically since 1987 (33% to 65% ).
[Fortunately, in what way, for whom? Could it be the vaccines are worthless??? ]
https://www.vaccineshoppe.com/US_PDF/Fluzone_P-free_2002.2003_4675.4681.pdf
Source for the Package insert for Fluzone 'preservative free' 2002-2003 Formula.
If you dont want to download this 132K .PDF file, here are a few highlights:
[original is 8 pages]
Aventis Pasteur Inc.
Swiftwater PA 18370 USA"...is a sterile suspension prepared from influenza viruses propagated in chicken embryos. The virus-containing fluids are harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using Polyethylene Glycol p-Isooctylphenyl Ether (Triton r X-100 - A registered trademark of Rohm and Haas, Co.) producing a "split-antigen." The split-antigen is then further purified by chemical means and suspended in sodium phosphate-buffered isotonic sodium chloride solution. Fluzone has been standardized according to USPHS requirements for the 2002-2003 influenza season and is formulated to contain 45 micrograms (µg) hemagglutinin (HA) per 0.5 mL dose, in the recommended ratio of 15 µg HA each, representative of the following three prototype strains: A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) (an A/Moscow/10/99-like strain) and B/Hong Kong/1434/2002 (a B/Hong Kong/330/2001-like strain). 1 Gelatin 0.05% is added as a stabilizer. Fluzone is supplied in two unit dose preservative-free presentations distinguished by a pink syringe plunger rod: a 0.25 mL prefilled syringe (for pediatric use) and a 0.5 mL prefilled syringe; both are formulated without preservatives but contain a trace amount of thimerosal [(contains 49.6% mercury),(<=0.5 µg Hg/0.25 mL dose) (<=1.0 µg Hg/0.5 mL dose)] from the manufacturing process. Fluzone is also supplied in two other presentations: a 0.5 mL prefilled syringe and 5 mL vial of vaccine, of which both contain the preservative thimerosal [(mercury containing compound), 25 µg mercury/0.5 mL dose]. Fluzone, after shaking syringe/vial well, is essentially clear and slightly opalescent in color. ANTIBIOTICS ARE NOT USED IN THE MANUFACTURE OF FLUZONE."
"Among persons aged >=65 years, influenza vaccination levels increased from 33% in 1989 to 66% in 1999, surpassing the Healthy People 2000 goal of 60%. "
"Influenza A viruses are further categorized into subtypes based on two surface antigens: hemagglutinin (H) and neuraminidase (N). Influenza B viruses are not categorized into subtypes. Both influenza A and B viruses are further separated into groups based on antigenic characteristics. New influenza virus variants result from frequent antigenic change (i.e., antigenic drift), resulting from point mutations that occur during viral replication. Influenza B viruses undergo antigenic drift less rapidly than influenza A viruses. Since 1977, influenza A (H1N1) viruses, influenza A (H3N2) viruses, and influenza B viruses have been in global circulation. A person's immunity to the surface antigens, especially hemagglutinin, reduces the likelihood of infection and the severity of disease if infection occurs. However, antibody against one influenza virus type or subtype confers little or no protection against another virus type or subtype. Furthermore, antibody to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype. The frequent development of antigenic variants through antigenic drift is the virologic basis for seasonal epidemics and the reason for the possible incorporation of >=1 new strains in each year's influenza vaccine." "Influenza-related deaths can result from pneumonia as well as from exacerbations of cardiopulmonary conditions and other chronic diseases. In studies of influenza epidemics occurring from 1972-1973 through 1994-1995, excess deaths (ie, the number of influenza-related deaths above a projected baseline of expected deaths) occurred during 19 of 23 influenza epidemics. During those 19 influenza seasons, estimated rates of influenza-associated deaths ranged from approximately 30 to >150 deaths/100,000 persons aged >=65 years. Older adults account for >90% of deaths attributed to pneumonia and influenza. From 1972-1973 through 1994-1995, >20,000 influenza-associated deaths were estimated to occur during each 11 different US epidemics, and >40,000 influenza-associated deaths were estimated for each of 6 of these 11 epidemics. In the US, pneumonia and influenza deaths might be increasing in part because the number of older persons is increasing."
[Note: deaths per 100,000 in the >65 age group have increased after 1980.]
"SAFETY AND EFFECTIVENESS OF FLUZONE (SUBVIRION) IN INFANTS BELOW THE AGE OF 6 MONTHS HAVE NOT BEEN ESTABLISHED."
"The majority of influenza vaccine distributed in the US contains thimerosal, a mercury-containing compound, as a preservative. Thimerosal has been used in US vaccines since the 1930s." [read rest on pg 4-5]
"CONTRAINDICATIONS
INFLUENZA VIRUS IS PROPAGATED IN EGGS FOR THE PREPARATION OF INFLUENZA VIRUS VACCINE. THEREFORE, FLUZONE SHOULD NOT BE ADMINISTERED TO ANYONE WITH A HISTORY OF HYPERSENSITIVITY (ALLERGY), ESPECIALLY ANAPHYLACTIC REACTIONS, TO EGGS OR EGG PRODUCTS. IT IS ALSO A CONTRAINDICATION TO ADMINISTER FLUZONE TO INDIVIDUALS KNOWN TO BE SENSITIVE TO THIMEROSAL. EPINEPHRINE INJECTION (1:1000) MUST BE IMMEDIATELY AVAILABLE SHOULD AN ACUTE ANAPHYLACTIC REACTION OCCUR DUE TO ANY COMPONENT OF FLUZONE.Fluzone should not be administered to patients with acute respiratory or other active infections or illnesses. Immunization should be delayed in a patient with an active neurologic disorder, but should be considered when the disease process has been stabilized.
WARNINGS
Fluzone should not be administered to individuals who have a prior history of Guillain-BarrT syndrome (GBS). If Fluzone is administered to immunosuppressed persons, the expected antibody response may not be obtained. As with any vaccine, vaccination with Fluzone may not protect 100% of susceptible individuals.""Since the likelihood of febrile convulsions is greater in children 6 months through 35 months of age, special care should be taken in weighing relative risks and benefits of vaccination.
Prior to an injection of any vaccine, all known precautions should be taken to prevent adverse reactions. This includes a review of the patient's history with respect to possible sensitivity to the vaccine or similar vaccine, to possible sensitivity to dry natural latex rubber, previous immunization history, current health status (see CONTRAINDICATIONS and WARNINGS sections) and a knowledge of the current literature concerning the use of the vaccine under consideration. Special care should be taken to prevent injection into a blood vessel."
"Systemic Reactions
Fever, malaise, myalgia, and other systemic symptoms can occur following vaccination and most often affect persons who have had no exposure to the influenza virus antigens in the vaccine (e.g., young children).1,14 These reactions begin 6 to 12 hours after vaccination and can persist for 1-2 days. Recent placebo-controlled trials demonstrate that among older persons and healthy young adults, administration of split-virus vaccine is not associated with higher rates of systemic symptoms (e.g., fever, malaise, myalgia, and headache) when compared with placebo injections. 1 Immediate - presumably allergic - reactions (e.g., hives, angioedema, allergic asthma, and systemic anaphylaxis) rarely occur after influenza vaccination. These reactions probably result from hypersensitivity to certain vaccine components; the majority of reactions likely are caused by residual egg protein. Although current influenza vaccines contain only a limited quantity of egg protein, this protein can induce immediate hypersensitivity reactions among persons who have severe egg allergy. Persons who have experienced hives, have had swelling of the lips or tongue, or have experienced acute respiratory distress or collapse after eating eggs should consult a physician for appropriate evaluation to help determine if vaccine should be administered. Persons who have documented immunoglobulin E (IgE)--mediated hypersensitivity to eggs--including those who have had occupational asthma or other allergic responses to egg protein--also might be at increased risk for allergic reactions to influenza vaccine, and consultation with a physician should be considered. Protocols have been published for safely administering influenza vaccine to persons with egg allergies. 1,15 [.. continues on with GBS, etc]
Although influenza is associated with more disease, hospitalization, and death in "at risk" populations, no adequate controlled studies exist which prove that influenza vaccine reduces the incidence of influenza in these groups.
Past studies by NH Arden, et al, of type A(H3N2) influenza vaccine in nursing home patients yielded an average of only 27 percent efficacy with four studies demonstrating vaccine efficacy at 0, 2, 8 and 9 percent. Poor vaccine efficacy can even occur when the vaccine virus is "essentially identical" to that virus which is causing the outbreak. For influenza B vaccine, studies conducted by Arden range from 0 percent to 36 percent effective, averaging 21 percent.
Considering that more than 90 percent of pneumonia and influenza deaths occur in persons 65 years of age or older, but that about 65 percent of all deaths (from any cause) occur in this age group anyway, it is nearly impossible to prove if flu shots significantly increase life expectancy in the elderly. Indeed one study of elderly Medicare patients in Ohio and Pennsylvania, published in Options for the Control of Influenza II, showed "no demonstrated effect of influenza vaccine in preventing death or limiting the length of hospital stay."
Instead of being an effective prevention, evidence indicates that flu shots may be useless. Although endorsed and funded by federal and state governments the shots seem only to benefit the companies that make them, public health bureaucrats who promote them, and medical personnel who administer them.
http://www.korenpublications.com/newsletters/dec2001.html
Flu Shots and Alzheimer's
Many people have asked me to reprint the flu shot information.
Here it is from our Oct 2000 newsletter:"According to Hugh Fudenberg, MD, the world's leading immunogeneticist and 13th most quoted biologist of our times (nearly 850 papers in peer review journals), if an individual has had five consecutive flu shots between 1970 and 1980 (the years studied), his/her chances of getting Alzheimer's Disease is ten times higher than if they had one, two or no shots. (1)
I asked Dr. Fudenberg why this was so and he said it was due to the mercury that is in every flu shot (and many childhood shots). The gradual mercury buildup in the brain causes cognitive dysfunction.
Is that why Alzheimer's is expected to quadruple? (2)
(1) Dr. Fudenberg at the NVIC International Vaccine Conference, Arlington, VA September, 1997. Quoted with permission.
(2) John's Hopkins Newsletter Nov 1998.
Note: Dr. Fudenberg's web site is: http://members.aol.com/nitrf
Ingri Cassel, President
Vaccination Liberation - Idaho Chapter
P.O. Box 1444
Coeur d'Alene, Idaho 83816
(208)255-2307/ 765-8421
vaclib@coldreams.com
"Free Your Mind....From The Vaccine Paradigm"
www.vaclib.org
Page last modified: - - 10/09/2002 09:35:05 http://www.vaclib.org/basic/fluindex.htm
Index of Articles for Vaccination
Liberation. Home page of
Vaccination Liberation
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.